PubRank

James A Shayman

Author PubWeight™ 52.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 2010 1.62
2 Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J Virol 2009 1.61
3 A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 2007 1.61
4 Alpha-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency. Circulation 2005 1.28
5 Lysosomal phospholipase A2 and phospholipidosis. Mol Cell Biol 2006 1.23
6 Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 2008 1.21
7 Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice. Hepatology 2009 1.16
8 Disruption of the glucosylceramide biosynthetic pathway in Aspergillus nidulans and Aspergillus fumigatus by inhibitors of UDP-Glc:ceramide glucosyltransferase strongly affects spore germination, cell cycle, and hyphal growth. FEBS Lett 2002 1.16
9 Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 2003 1.15
10 Lysosomal phospholipase A2 is selectively expressed in alveolar macrophages. J Biol Chem 2004 1.11
11 Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 2010 1.10
12 Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol 2009 1.09
13 Cloning and characterization of a lysosomal phospholipase A2, 1-O-acylceramide synthase. J Biol Chem 2002 1.07
14 Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS One 2010 1.04
15 Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice. J Biol Chem 2007 1.02
16 The secretion and uptake of lysosomal phospholipase A2 by alveolar macrophages. J Immunol 2008 1.00
17 An in vitro model of Fabry disease. J Am Soc Nephrol 2005 1.00
18 A role for lysosomal phospholipase A2 in drug induced phospholipidosis. Drug Metab Lett 2007 1.00
19 Ceramide 1-phosphate, a mediator of phagocytosis. J Biol Chem 2005 0.99
20 Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin Exp Pharmacol Physiol 2008 0.99
21 Calcium-independent phospholipase A2 beta is dispensable in inflammasome activation and its inhibition by bromoenol lactone. J Innate Immun 2009 0.97
22 Increased hepatic insulin action in diet-induced obese mice following inhibition of glucosylceramide synthase. PLoS One 2010 0.95
23 Structure and function of lysosomal phospholipase A2: identification of the catalytic triad and the role of cysteine residues. J Lipid Res 2005 0.94
24 The role of negatively charged lipids in lysosomal phospholipase A2 function. J Lipid Res 2009 0.93
25 Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem 2013 0.92
26 The acylation of lipophilic alcohols by lysosomal phospholipase A2. J Lipid Res 2007 0.92
27 Mapping mechanisms and charting the time course of premature cell senescence and apoptosis: lysosomal dysfunction and ganglioside accumulation in endothelial cells. Am J Physiol Renal Physiol 2007 0.92
28 Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineage. J Biol Chem 2011 0.90
29 Src kinase mediates the regulation of phospholipase C-gamma activity by glycosphingolipids. J Biol Chem 2003 0.90
30 Sphingosine kinase 1-mediated inhibition of Fas death signaling in rheumatoid arthritis B lymphoblastoid cells. Arthritis Rheum 2006 0.90
31 Induction of lysosomal phospholipase A2 through the retinoid X receptor in THP-1 cells. J Lipid Res 2004 0.89
32 Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J Lipid Res 2008 0.88
33 Regulation of phospholipase C-gamma activity by glycosphingolipids. J Biol Chem 2002 0.88
34 Positional specificity of lysosomal phospholipase A2. J Lipid Res 2006 0.88
35 Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 2011 0.87
36 Granulocyte colony-stimulating factor primes NADPH oxidase in neutrophils through translocation of cytochrome b(558) by gelatinase-granule release. J Lab Clin Med 2002 0.86
37 The measurement of lysosomal phospholipase A2 activity in plasma. J Lipid Res 2010 0.86
38 Role for lysosomal phospholipase A2 in iNKT cell-mediated CD1d recognition. Proc Natl Acad Sci U S A 2013 0.85
39 Differential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse. Am J Physiol Heart Circ Physiol 2009 0.84
40 Regulation of polymorphonuclear leukocyte degranulation and oxidant production by ceramide through inhibition of phospholipase D. Blood 2002 0.84
41 Globoside promotes activation of ERK by interaction with the epidermal growth factor receptor. Biochim Biophys Acta 2012 0.82
42 Ceramide-1-phosphate in phagocytosis and calcium homeostasis. Adv Exp Med Biol 2010 0.81
43 Ceramide inhibition of phospholipase D and its relationship to RhoA and ARF1 translocation in GTP gamma S-stimulated polymorphonuclear leukocytes. Blood 2003 0.81
44 Alpha-galactosidase A deficiency leads to increased tissue fibrin deposition and thrombosis in mice homozygous for the factor V Leiden mutation. Stroke 2006 0.81
45 1-O-acylceramides are natural components of human and mouse epidermis. J Lipid Res 2013 0.80
46 Ceramide kinase promotes Ca2+ signaling near IgG-opsonized targets and enhances phagolysosomal fusion in COS-1 cells. J Lipid Res 2007 0.80
47 Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile Sandhoff disease mice. Neurochem Res 2013 0.80
48 Glycosphingolipid Mediated Caveolin-1 Oligomerization. J Glycomics Lipidomics 2012 0.79
49 Phagocytic signaling molecules in lipid rafts of COS-1 cells transfected with FcgammaRIIA. Biochem Biophys Res Commun 2005 0.78
50 Alpha-galactosidase A in vascular disease. Trends Cardiovasc Med 2007 0.77
51 Endothelial nitric oxide synthase uncoupling and microvascular dysfunction in the mesentery of mice deficient in α-galactosidase A. Am J Physiol Gastrointest Liver Physiol 2013 0.77
52 Lysosomal phospholipase A2: a novel player in host immunity to Mycobacterium tuberculosis. Eur J Immunol 2014 0.77
53 A fluorogenic phospholipid for the detection of lysosomal phospholipase A2 activity. Anal Biochem 2012 0.77
54 Enhanced phagocytosis through inhibition of de novo ceramide synthesis. J Biol Chem 2002 0.76
55 Thinking about rare kidney diseases. J Am Soc Nephrol 2005 0.76